Aldeyra Therapeutics (ALDX) Preferred Stock Liabilities (2013 - 2014)
Aldeyra Therapeutics (ALDX) posted Preferred Stock Liabilities of $38.5 million for Q1 2014, little changed on a QoQ basis from $38.3 million in Q4 2013.
Aldeyra Therapeutics (ALDX) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Aldeyra Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $38.5 million for Q1 2014.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $38.5 million in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $38.5 million (changed N/A YoY) and the FY2013 annual result came in at $38.3 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $38.5 million for Q1 2014 at Aldeyra Therapeutics, roughly flat from $38.3 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $38.5 million in Q1 2014 and bottomed at $38.3 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | - |
| 10 | Aldeyra Therapeutics | 93.19 Mn | 93.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 38.51 Mn |
| Dec 31, 2013 | 38.32 Mn |